News
Company News: Agena Bioscience Launches High-Throughput, Low-Cost SARS-CoV-2 Detection Panel in Europe with CE-IVD Marking
Agena Bioscience, a global provider of low cost and high-throughput molecular testing solutions, today announced that it has obtained CE-IVD marking for its SARS-CoV-2 Panel, an in vitro diagnostic test for the qualitative detection of the SARS-CoV-2 coronavirus that causes COVID-19.
Company News: T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy
T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced they have signed an agreement to provide technology transfer and cGMP clinical manufacturing of T-knife’s T1367 T-cell receptor (TCR) program.
Company News: T-knife Completes € 66 Million Series A Financing to Develop Next-Generation T-Cell Therapies
— T-knife’s proprietary humanized mouse platform (HuTCR) T-cell receptors expected to provide superior affinity/specificity properties
— Series A round led by Versant Ventures and RA Capital Management, with strong participation from seed investors Andera Partners and BIVF
T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, announced today the closing of a €66 million Series A round of financing.
Company News: BellaSeno Announces First-In-Human Trial of its Novel, Absorbable Soft Tissue Reconstruction Scaffold and Granting of Key U.S. Patent
– First patient with Pectus Excavatum congenital defect has undergone surgery in Australia
– Minimally invasive procedure and fully absorbable scaffold expected to provide for improved safety and recovery
– Key U.S. patent granted for the design and porosity of Senella® platform
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the initiation of a first-in-human trial of its novel, absorbable soft tissue reconstruction scaffold (Senella®).